[Coronary allograft vasculopathy: pathophysiological interaction between the immune system, infections and metabolic syndrome].
Cardiac allograft vasculopathy is still the main cause of long-term graft loss after heart transplantation. Indeed, recent advances in immunosuppression management led to a significant improvement in short-term survival, while long-term death rate did not change significantly in the last 20 years. In this paper, we will review the latest advances in the understanding of this peculiar form of atherosclerosis, focusing on the mechanisms that can be potentially targeted by specific therapeutic interventions.
Potena
Luciano
L
Istituto di Malattie dell'Apparato Cardiovascolare, Università degli Studi, Bologna. luciano.potena2@unibo.it
Ferrara
Rossella
R
Mocarski
Edward S
ES
Lewis
David B
DB
Cooke
John P
JP
Grigioni
Francesco
F
Coccolo
Fabio
F
Magnani
Gaia
G
Fallani
Francesco
F
Magelli
Carlo
C
Valantine
Hannah A
HA
Branzi
Angelo
A
D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives / Q000378:metabolism; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000209:etiology* / Q000276:immunology / Q000378:metabolism / Q000401:mortality / Q000517:prevention & control / Q000628:therapy; D003586:Cytomegalovirus Infections / Q000150:complications / Q000517:prevention & control; D004195:Disease Models, Animal; D004730:Endothelium, Vascular / Q000502:physiology; D006084:Graft Rejection; D006085:Graft Survival; D016027:Heart Transplantation / Q000009:adverse effects* / Q000401:mortality; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D024821:Metabolic Syndrome / Q000150:complications; D011788:Quality of Life; D018570:Risk Assessment; D012307:Risk Factors; D012377:Rodentia; D015607:Stents; D013997:Time Factors
D000960:Hypolipidemic Agents; D007166:Immunosuppressive Agents; C018524:N,N-dimethylarginine; D001120:Arginine